Together, in addition to inhibition of liver tumorigenesis, loss of STK25 in both HCC models substantially suppressed all the pathologic features of NASH, including hepatic steatosis, inflammation, and fibrosis. Here, STK25 is linked to metabolic dysfunction-associated steatohepatitis.